Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,287,080 papers from all fields of science
Search
Sign In
Create Free Account
BMS188797
Known as:
BMS-188797
An analog of paclitaxel with antineoplastic activity. BMS-188797 binds to and stabilizes the resulting microtubules, thereby inhibiting microtubule…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Microtubule Process
Broader (1)
Taxoids
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2006
2006
Phase I Study of the Taxane BMS-188797 in Combination with Carboplatin Administered Every 3 Weeks in Patients with Solid Malignancies
M. Fishman
,
C. Garrett
,
+9 authors
D. Sullivan
Clinical Cancer Research
2006
Corpus ID: 300327
Rationale: BMS-188797 is one of several novel taxanes in ongoing clinical development. It has superior activity in experimental…
Expand
Review
2006
Review
2006
Gateways to clinical trials.
M. Bayés
,
X. Rabasseda
,
J. Prous
Methods and Findings in Experimental and Clinical…
2006
Corpus ID: 38008399
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
2006
2006
Phase I Study of theTaxane BMS-188797 in Combinationwith Carboplatin Administered Every 3 Weeks in Patients with SolidMalignancies
M. Fishman
,
C. Garrett
,
+9 authors
D. Sullivan
2006
Corpus ID: 36600914
Rationale: BMS-188797 is one of several novel taxanes in ongoing clinical development. It has superior activity in experimental…
Expand
2005
2005
Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies
C. Garrett
,
M. Fishman
,
+8 authors
D. Sullivan
Clinical Cancer Research
2005
Corpus ID: 13642964
Purpose: Preclinical studies show that BMS-188797 has a broad spectrum of antitumor activity in in vitro cytotoxicity assays and…
Expand
2005
2005
A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours
A. du Bois
,
B. Jung
,
A. Loehr
,
T. Schaller-Kranz
,
M. Cohen
,
N. Frickhofen
British Journal of Cancer
2005
Corpus ID: 14640132
This phase I study investigated the maximum tolerated dose and pharmacokinetics of a 3-weekly administration of BMS-188797, a…
Expand
2005
2005
Gateways to clinical trials.
M. Bayés
,
X. Rabasseda
,
J. Prous
Methods and Findings in Experimental and Clinical…
2005
Corpus ID: 8811644
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
2004
2004
Head and neck squamous cell carcinoma cell lines are highly sensitive to the new taxanes, BMS-184476, BMS-188797, in vitro.
M. Raitanen
,
J. Pulkkinen
,
J. Kulmala
,
R. Grénman
Anticancer Research
2004
Corpus ID: 10515461
BACKGROUND The development of synthetic taxanes targets at increasing solubility of the drug, improved clinical efficacy and…
Expand
2004
2004
Gateways to clinical trials.
M. Bayés
,
X. Rabasseda
,
J. Prous
Methods and Findings in Experimental and Clinical…
2004
Corpus ID: 36014232
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand
2003
2003
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies.
R. Advani
,
G. Fisher
,
+5 authors
B. Sikic
Clinical Cancer Research
2003
Corpus ID: 15123940
PURPOSE The purpose of this study was to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE